Comanche Biopharma is focused on developing an innovative siRNA (small interfering RNA) therapy aimed at addressing the root cause of preeclampsia, a serious pregnancy complication that affects millions of women globally. Their investigational drug, CBP-4888, targets specific mRNA isoforms of the soluble fms-like tyrosine kinase-1 (sFlt1) protein, which is known to contribute to the disease's progression. By utilizing a biologically-based approach that leverages the body's natural mechanisms for regulating protein production, Comanche aims to reduce the harmful levels of sFlt1 in pregnant women, potentially alleviating symptoms and improving outcomes for both mothers and their babies.

The company is committed to making this groundbreaking therapy accessible and affordable, particularly for underserved populations disproportionately affected by preeclampsia. With a strong emphasis on ethical representation in clinical trials, Comanche Biopharma is dedicated to addressing the urgent public health crisis posed by preeclampsia, which currently has no existing therapies to modify its progression. Their mission is not only to develop a definitive treatment but also to ensure that it reaches women worldwide, thereby enhancing maternal health and reducing the risks associated with this life-threatening condition.

United States

Comanche is a biopharmaceutical company developing novel siRNA molecules for the treatment of preeclampsia. Our purpose is to lower the risks of pregnancy and prematurity worldwide by safely sustaining natural pregnancy and allowing for fetal maturation. We envision a world where all pregnant women have access to safe and effective therapies that are evidence-based, cost-effective and sustainable. Our mission is to prevent or treat preeclampsia at its root cause.

Comanche Biopharma

Company Details